Liftstream is an executive search recruitment company in the life sciences sector
AVROBIO, a clinical-stage biotechnology company developing transformative cell and gene therapies targeting cancer and rare diseases, has made three senior appointments. Joining the firm’s leadership team are Kim Warren, Head of Operations, Chris Mason, Chief Science Officer, and Deanna Petersen, Chief Business Officer.
The New Year brings a period of reflection, what will you change in the year ahead and how will you do it? There are some clear ways in which the effectiveness of the board can be improved by the way in which the nominations and governance committee discharge their responsibilities. Here we listed 5 resolutions for an effective nominations committee. Click the following links to read detailed articles on each recommendation.
Immatics Biotechnologies, a biopharmaceutical company focused on cancer immunotherapy, has appointed Katina Dorton as CFO. “Dorton’s experience working with innovative life sciences companies and strong track record leading corporate transactions and managing financial operations makes her an excellent addition to the Immatics senior management team,” commented Immatics Chairman Peter Chambré.
Aegerion Pharmaceuticals, a biopharmaceutical company dedicated to the development and commercialisation of innovative therapies for patients with debilitating rare diseases, has appointed Mary Szela as CEO and a member of board of directors. Szela replaces interim CEO Sandford Smith who took over after the resignation of former CEO Marc Beer in July 2015. After stepping down as Interim CEO, Smith was appointed chairman of the board of directors, allowing him to continue to work closely with the management team to maintain the momentum on key company initiatives.
Idera Pharmaceuticals, a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, has appointed Maxine Gowen to its board of directors.
Blueprint Medicines, a company discovering and developing highly selective investigational kinase medicines for patients with genomically defined diseases, has appointed Kathryn (Kate) Haviland as Chief Business Officer, who will be responsible for the firm’s corporate strategy, business development, corporate communications and investor relations functions.
Codiak BioSciences, a venture-backed start-up in Cambridge, Mass, has appointed Ariel Jasie as Chief Business Officer, Linda Bain as CFO and Konstantin Konstantinov as Senior Vice President.
Rodin Therapeutics, a biotechnology company developing therapeutics for neurological disorders based in Cambridge, Mass, has appointed Samantha Singer as an independent member of the company’s board of directors. Singer is COO of the Broad Institute of MIT and Harvard, where she oversees the institute’s human resources, finance, facilities, and information technology teams, in addition to the Office of Strategic Alliances and Partnering.
Intellia Therapeutics, a genome editing company based in Cambridge, Massachusetts, has named Caroline Dorsa to its Board of Directors. Her appointment will help advance the company’s mission of developing therapeutics utilizing CRISPR/Cas9 gene-editing technology.Watch Full Movie Online Streaming Online and Download
Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™ based in Cambridge, Mass, has appointed Elizabeth (Betsy) Nabel to its Board of Directors. Nable is the President of Harvard-affiliated Brigham and Women’s Health Care (BWHC) and a Professor of Medicine at Harvard Medical School.